STOCK TITAN

OKYO Pharma (OKYO) director discloses stock and option holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

OKYO Pharma Ltd director Simon Willy Jules has filed a Form 3 reporting his initial ownership in the company. He holds 6,435 shares of common stock directly and 8,948 shares indirectly through his spouse. He also reports multiple option awards over common stock, including grants covering 12,500 shares at an exercise price of $1.50 per share and 5,000 shares at $1.65 per share, with expiration dates running from 2033 to 2035. These positions show his existing equity and option exposure rather than new market transactions.

Positive

  • None.

Negative

  • None.
Insider Simon Willy Jules
Role null
Type Security Shares Price Value
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding COMMON STOCK -- -- --
holding COMMON STOCK -- -- --
Holdings After Transaction: Options — 1,538 shares (Direct, null); COMMON STOCK — 6,435 shares (Direct, null); COMMON STOCK — 8,948 shares (Indirect, Holding of spouse)
Footnotes (1)
Direct common shares 6,435 shares Total common stock held directly following reported holdings
Indirect common shares (spouse) 8,948 shares Common stock held indirectly as holding of spouse
Option block at $1.50 12,500 underlying shares Options over common stock at $1.50, expiring 2035-03-25
Option block at $1.46 13,334 underlying shares Options over common stock at $1.46, expiring 2034-03-13
Option block at $1.65 5,000 underlying shares Options over common stock at $1.65, expiring 2033-11-24
Option block at $2.13 1,540 underlying shares Options over common stock at $2.13, expiring 2033-03-14
Form 3 regulatory
"Simon Willy Jules has filed a Form 3 reporting his initial ownership."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
indirect ownership financial
"He reports 8,948 shares of common stock as indirect ownership through his spouse."
exercise price financial
"Option awards include grants at an exercise price of $1.50, $1.46, $1.65 and $2.13 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The options have an expiration date range from 2033 to 2035."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying common stock financial
"Each option grant references underlying common stock with specified share amounts."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Simon Willy Jules

(Last)(First)(Middle)
C/O OKYO PHARMA LTD,
14-15 CONDUIT STREET

(Street)
LONDONW1S 2XJ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK6,435D
COMMON STOCK8,948IHolding of spouse
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options03/14/202403/14/2033common stock1,538$2.13D
Options03/14/202503/14/2033common stock1,538$2.13D
Options03/14/202603/14/2033common stock1,538$2.13D
Options03/14/202703/14/2033common stock1,540$2.13D
Options11/24/202411/24/2033common stock5,000$1.65D
Options11/24/202511/24/2033common stock5,000$1.65D
Options11/24/202611/24/2033common stock5,000$1.65D
Options11/24/202711/24/2033common stock5,000$1.65D
Options03/13/202503/13/2034common stock13,333$1.46D
Options03/13/202603/13/2034common stock13,334$1.46D
Options03/13/202703/13/2034common stock13,333$1.46D
Options01/29/202601/29/2035common stock3,212$1.6D
Options01/29/202701/29/2035common stock3,212$1.6D
Options01/29/202801/29/2035common stock3,212$1.6D
Options01/29/202901/29/2035common stock3,212$1.6D
Options03/25/202603/25/2035common stock12,500$1.5D
Options03/25/202703/25/2035common stock12,500$1.5D
Options03/25/202803/25/2035common stock12,500$1.5D
Options03/25/202903/25/2035common stock12,500$1.5D
Explanation of Responses:
/s/ Willy Simon06/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Simon Willy Jules report in his OKYO Pharma (OKYO) Form 3 filing?

Simon Willy Jules reports his initial ownership in OKYO Pharma, including direct and indirect common stock plus several option awards. The filing outlines his equity exposure as a director, without indicating any recent purchases or sales.

How many OKYO Pharma common shares does Simon Willy Jules hold directly and indirectly?

The Form 3 shows direct ownership of 6,435 OKYO Pharma common shares and indirect ownership of 8,948 shares through his spouse. Together, these figures outline his reported share position at the time of the filing.

What stock options for OKYO Pharma does Simon Willy Jules report holding?

He reports multiple option grants over OKYO Pharma common stock, including blocks of 12,500 shares at $1.50, 13,334 and 13,333 shares at $1.46, and 5,000 shares at $1.65. Additional smaller grants are listed at an exercise price of $2.13.

When do the OKYO Pharma stock options held by Simon Willy Jules expire?

The options disclosed in the Form 3 have expiration dates ranging from 2033-03-14 to 2035-03-25. These long-dated expirations indicate multi‑year potential for conversion into common stock if exercised.

Are there any buy or sell transactions in Simon Willy Jules’s OKYO Pharma Form 3?

The Form 3 records holdings rather than transactions, with transaction codes listed as unknown and no buy or sell amounts. It functions as an initial statement of beneficial ownership instead of reporting new market trades.